Tennessee Senate Bill SB1626

Tennessee 2025-2026 Regular Session

• Introduced: 1/13/26

Caption

AN ACT to amend Tennessee Code Annotated, Title 4; Title 56 and Title 71, relative to cancer testing.

Impact

This legislation is poised to transform healthcare access for individuals at risk of cancer in Tennessee. By mandating coverage without cost-sharing, it removes financial barriers that might prevent at-risk individuals from seeking necessary tests. The expected result is an improved public health outcome, as more people will be able to undergo vital screenings and genetic assessments leading to early detection and treatment. Additionally, this change can enhance overall patient awareness and education regarding cancer risks and interventions.

Summary

Senate Bill 1626 focuses on amending the Tennessee Code to ensure greater access to cancer testing, particularly through provisions requiring health insurance plans to cover clinical genetic testing for individuals with a personal or family history of cancer. The bill's main objective is to eliminate cost-sharing requirements for evidenced-based cancer imaging and genetic tests, making these essential services more accessible to individuals at risk. By prioritizing health services based on clinical guidelines, the bill aims to improve early detection and treatment outcomes for cancer patients.

Sentiment

The sentiment surrounding SB1626 appears to be largely supportive among medical professionals and advocates for health equity. Supporters view the bill as a necessary advancement in cancer prevention and treatment, citing its role in addressing disparities in healthcare access. However, there may be underlying concerns regarding the financial implications for insurers, particularly on how increased coverage requirements could affect premium costs, leading to debates about the balance between health equity and insurance sustainability.

Contention

Some points of contention regarding SB1626 may arise from discussions on the fiscal impact on insurance providers and the feasibility of implementing these coverage changes. Critics could argue that such mandates may result in increased insurance premiums, impacting the overall cost of healthcare. Additionally, questions may emerge about the extent of genetic testing required and the criteria for determining who qualifies as at-risk, as this could impact healthcare providers' practices. Thus, while the intent to improve access to cancer testing is widely supported, there remain nuanced discussions about its execution and potential broader implications on the insurance market.